永安药业实控人方拟减持 首季亏损营业收入已连降3年

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced a share reduction plan by its controlling shareholder, Huanggang Yong'an Pharmaceutical Co., Ltd., which holds 10,529,232 shares, representing 3.64% of the total share capital after excluding shares in the repurchase account. The plan involves reducing up to 2,632,300 shares, or 0.91% of the total share capital, within three months without changing control of the company [1][2]. Financial Performance - In Q1 2025, Yong'an Pharmaceutical reported revenue of 171 million yuan, a year-on-year decrease of 12.96%. The net profit attributable to shareholders was -4.37 million yuan, down from 28.68 million yuan in the same period last year. The net profit after excluding non-recurring items was -6.67 million yuan, compared to 19.97 million yuan in the previous year [2]. - For the years 2021 to 2024, Yong'an Pharmaceutical's revenue was 1.565 billion yuan, 1.462 billion yuan, 973 million yuan, and 839 million yuan, respectively. The net profit attributable to shareholders for the same years was 111 million yuan, 140 million yuan, -12.31 million yuan, and 61.76 million yuan. The net profit after excluding non-recurring items was 91.82 million yuan, 122 million yuan, -75.99 million yuan, and 26.76 million yuan [2]. - The company expects a significant decline in net profit for the first half of 2025, projecting a range of 10.0177 million to 15.0177 million yuan, representing a decrease of 80.91% to 71.39% year-on-year. The net profit after excluding non-recurring items is expected to be between 1.8883 million and 2.8083 million yuan, down 94.75% to 92.19% year-on-year [1].